Patents by Inventor Paul J. Hergenrother
Paul J. Hergenrother has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124462Abstract: New synthetic methods to provide access to previously unexplored functionality at the C8 position of substituted imidazo[5,1-d][1,2,3,5]tetrazines of Formula I. Through synthesis and evaluation of a suite of compounds with a range of aqueous stabilities (from 0.5 to 40 hours), a predictive model for imidazotetrazine hydrolytic stability based on the Hammett constant of the C8 substituent was derived. Promising compounds were identified that possess activity against a panel of GBM cell lines, appropriate hydrolytic and metabolic stability, and brain-to-serum ratios dramatically elevated relative to TMZ, leading to lower hematological toxicity profiles and superior activity to TMZ in a mouse model of GBM.Type: ApplicationFiled: December 16, 2022Publication date: April 18, 2024Applicant: The Board of Trustees of the University of IllinoisInventors: Paul J. HERGENROTHER, Timothy M. FAN, Riley L. SVEC
-
Publication number: 20240116911Abstract: Disclosed herein are antibacterial compounds that accumulate in Gram-negative bacteria, methods of preparing the compounds, and methods of using the compounds to inhibit or kill microbes, and methods of treating microbial infections, such as Gram-negative bacterial infections. Compounds selected for conversion to potential Gram-negative antibacterial compounds were identified based on compounds having low globularity and low flexibility. Amine substituents were then strategically added to the selected compounds to provide compounds having antibacterial activity against Gram-negative bacteria.Type: ApplicationFiled: June 29, 2023Publication date: April 11, 2024Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Paul J. Hergenrother, Emily Jane Geddes, Bryon Shane Drown, Stephen E. Motika, Erica Nicole Parker
-
Publication number: 20240109934Abstract: Novel Fusidic Acid (FA) based compounds that have equivalent potency against clinical isolates of Staphylococcus aureus (S. aureus) and Enterococcus faecium (E. faecium) as well as an improved resistance profile in vitro when compared to FA. Importantly, the new compounds display efficacy against a FA-resistant strain of Staphylococcus aureus in a soft-tissue murine infection model. This disclosure delineates the structural features of FA necessary for potent antibiotic activity and demonstrates that the resistance profile can be improved for this scaffold and target.Type: ApplicationFiled: January 13, 2022Publication date: April 4, 2024Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Paul J. HERGENROTHER, Martin GARCIA CHAVEZ
-
Publication number: 20240082241Abstract: Compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other cancer therapies that achieve the same or similar therapeutic effect.Type: ApplicationFiled: November 21, 2023Publication date: March 14, 2024Applicants: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, VANQUISH ONCOLOGY, INC., THE JOHNS HOPKINS UNIVERSITYInventors: Paul J. HERGENROTHER, Rachel C. BOTHAM, Timothy M. FAN, Mark J. GILBERT, Michael K. HANDLEY, Avadhut JOSHI, Gregory J. RIGGINS, Theodore M. TARASOW
-
Patent number: 11926877Abstract: A saliva-based testing method that bypasses the need for RNA isolation/purification is described herein. In experiments with inactivated SARS-CoV-2 virus spiked into saliva, this method has a limit of detection of 500-1000 viral particles per mL, rivalling the standard NP swab method. Initial studies showed excellent performance with 100 clinical samples. This saliva-based process is operationally simple, utilizes readily available materials, and can be easily implemented by existing testing sites thus allowing for high-throughput, rapid, and repeat testing of large populations.Type: GrantFiled: June 17, 2021Date of Patent: March 12, 2024Assignee: The Board of Trustees of the University of IllinoisInventors: Diana Rose Ranoa, Robin L. Holland, Fadi G. Alnaji, Kelsie J. Green, Leyi Wang, Christopher B. Brooke, Martin D. Burke, Timothy M. Fan, Paul J. Hergenrother
-
Patent number: 11858946Abstract: Disclosed are novel compounds that accumulate in Gram-negative bacteria. Also disclosed are method of antimicrobial treatment using the compounds.Type: GrantFiled: May 3, 2021Date of Patent: January 2, 2024Assignee: The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, Michelle Richter, Andrew Riley, Bryon S. Drown, Martin Chavez, Sarah Tasker, Alfredo Garcia
-
Patent number: 11844798Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: GrantFiled: December 22, 2020Date of Patent: December 19, 2023Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc., The Johns Hopkins UniversityInventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Avadhut Joshi, Gregory J. Riggins, Theodore M. Tarasow
-
Publication number: 20230391721Abstract: Small molecule ER? biomodulators that kill therapy-resistant ERa positive breast, ovarian, and endometrial cancer cells are disclosed. In one embodiment, the small molecule biomodulator has increased therapeutic utility because of an increased ability to kill therapy-resistant cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen, and fulvestrant/ICI). The small molecule biomodulators not only inhibit proliferation of the cancer cells but kills them, which prevents reactivation of tumors years later. Compounds of the invention, such as ErSO-DFP, are effective for treating ERa positive cancers such as breast cancer, ovarian cancer, uterine cancer, cervical carcinoma, endometrial cancer, and the like.Type: ApplicationFiled: October 21, 2021Publication date: December 7, 2023Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Paul J. HERGENROTHER, Matthew BOUDREAU
-
Patent number: 11833147Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.Type: GrantFiled: January 8, 2021Date of Patent: December 5, 2023Assignees: Vanquish Oncology, Inc., The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
-
Patent number: 11691967Abstract: Disclosed herein are antibacterial compounds that accumulate in Gram-negative bacteria, methods of preparing the compounds, and methods of using the compounds to inhibit or kill microbes, and methods of treating microbial infections, such as Gram-negative bacterial infections. Compounds selected for conversion to potential Gram-negative antibacterial compounds were identified based on compounds having low globularity and low flexibility. Amine substituents were then strategically added to the selected compounds to provide compounds having antibacterial activity against Gram-negative bacteria.Type: GrantFiled: March 11, 2019Date of Patent: July 4, 2023Assignee: The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, Emily Jane Geddes, Bryon Shane Drown, Stephen E. Motika, Erica Nicole Parker
-
Publication number: 20230183252Abstract: New synthetic methods to provide access to previously unexplored functionality at the C8 position of substituted imidazo[5,1-d][1,2,3,5]tetrazines of Formula I. Through synthesis and evaluation of a suite of compounds with a range of aqueous stabilities (from 0.5 to 40 hours), a predictive model for imidazotetrazine hydrolytic stability based on the Hammett constant of the C8 substituent was derived. Promising compounds were identified that possess activity against a panel of GBM cell lines, appropriate hydrolytic and metabolic stability, and brain-to-serum ratios dramatically elevated relative to TMZ, leading to lower hematological toxicity profiles and superior activity to TMZ in a mouse model of GBM.Type: ApplicationFiled: December 16, 2022Publication date: June 15, 2023Applicant: The Board of Trustees of the University of IllinoisInventors: Paul J. HERGENROTHER, Timothy M. FAN, Riley L. SVEC
-
Publication number: 20230158019Abstract: The discovery of mutant or fusion kinases that drive oncogenesis, and the subsequent approval of specific inhibitors for these enzymes, has been instrumental in the management of some cancers. However, acquired resistance remains a significant problem in the clinic, limiting the long-term effectiveness of most of these drugs. Herein is demonstrated a strategy to overcome this resistance through drug-induced MEK cleavage (via direct procaspase-3 activation) combined with targeted kinase inhibition. This combination effect is shown to be general across diverse tumor histologies (melanoma, lung cancer, and leukemia) and driver mutations (mutant BRAF or EGFR, fusion kinases EML4-ALK and BCR-ABL). Caspase-3-mediated degradation of MEK kinases results in sustained pathway inhibition and substantially delayed or eliminated resistance in cancer cells in a manner superior to combinations with MEK inhibitors.Type: ApplicationFiled: November 28, 2022Publication date: May 25, 2023Applicant: The Board of Trustees of the University of IllinoisInventors: Paul J. HERGENROTHER, Jessie PEH, Matthew BOUDREAU
-
Patent number: 11612598Abstract: Compositions and methods relating to induction of cell death such as in cancer cells are disclosed. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds in connection with modification of procaspases such as procaspase-3 are disclosed. In various embodiments, the compounds and compositions are capable of activation of procaspase-3.Type: GrantFiled: December 21, 2018Date of Patent: March 28, 2023Assignee: The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, Karson S. Putt, Quinn P. Peterson, Valerie Fako
-
Patent number: 11584718Abstract: A set of small molecules ER? biomodulators that kill therapy-resistant ER? positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.Type: GrantFiled: May 13, 2021Date of Patent: February 21, 2023Assignee: The Board of Trustees of the University of IllinoisInventors: David J. Shapiro, Paul J. Hergenrother, Matthew W. Boudreau
-
Patent number: 11530457Abstract: A saliva-based testing method that bypasses the need for RNA isolation/purification is described herein. In experiments with inactivated SARS-CoV-2 virus spiked into saliva, this method has a limit of detection of 500-1000 viral particles per mL, rivalling the standard NP swab method. Initial studies showed excellent performance with 100 clinical samples. This saliva-based process is operationally simple, utilizes readily available materials, and can be easily implemented by existing testing sites thus allowing for high-throughput, rapid, and repeat testing of large populations.Type: GrantFiled: June 17, 2021Date of Patent: December 20, 2022Assignee: The Board of Trustees of the University of IllinoisInventors: Diana Rose Ranoa, Robin L. Holland, Fadi G. Alnaji, Kelsie J. Green, Leyi Wang, Christopher B. Brooke, Martin D. Burke, Timothy M. Fan, Paul J. Hergenrother
-
Patent number: 11510919Abstract: The discovery of mutant or fusion kinases that drive oncogenesis, and the subsequent approval of specific inhibitors for these enzymes, has been instrumental in the management of some cancers. However, acquired resistance remains a significant problem in the clinic, limiting the long-term effectiveness of most of these drugs. Herein is demonstrated a strategy to overcome this resistance through drug-induced MEK cleavage (via direct procaspase-3 activation) combined with targeted kinase inhibition. This combination effect is shown to be general across diverse tumor histologies (melanoma, lung cancer, and leukemia) and driver mutations (mutant BRAF or EGFR, fusion kinases EML4-ALK and BCR-ABL). Caspase-3-mediated degradation of MEK kinases results in sustained pathway inhibition and substantially delayed or eliminated resistance in cancer cells in a manner superior to combinations with MEK inhibitors.Type: GrantFiled: November 16, 2018Date of Patent: November 29, 2022Assignee: The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, Jessie Peh, Matthew Boudreau
-
Publication number: 20220275464Abstract: A saliva-based testing method that bypasses the need for RNA isolation/purification is described herein. In experiments with inactivated SARS-CoV-2 virus spiked into saliva, this method has a limit of detection of 500-1000 viral particles per mL, rivalling the standard NP swab method. Initial studies showed excellent performance with 100 clinical samples. This saliva-based process is operationally simple, utilizes readily available materials, and can be easily implemented by existing testing sites thus allowing for high-throughput, rapid, and repeat testing of large populations.Type: ApplicationFiled: June 17, 2021Publication date: September 1, 2022Applicant: The Board of Trustees of the University of IllinoisInventors: Diana Rose RANOA, Robin L. HOLLAND, Fadi G. ALNAJI, Kelsie J. GREEN, Leyi WANG, Christopher B. BROOKE, Martin D. BURKE, Timothy M. FAN, Paul J. HERGENROTHER
-
Publication number: 20220226311Abstract: The blood-brain barrier penetrant procaspase-3-activating drug, PAC-1, has been identified as an effective approach to inducing immune stimulatory destruction of cancer cells. PAC-1 induces cleavage of MLH1 in cancer cells, and studies show that inactivation of MLH1 leads to increased mutational burden and neoantigen presentation by major histocompatibility complex (MHC) products. Herein is described a mechanistic-based strategy to bring the power of immunotherapy in an effective fashion for treatment of cancer.Type: ApplicationFiled: June 1, 2020Publication date: July 21, 2022Applicant: The Board of Trustees of the University of IllinoisInventors: Paul J. HERGENROTHER, Timothy M. FAN, Matthew BOUDREAU, William MONTGOMERY, Hyang-Yeon LEE, Marlies HAGER, Diana RANOA, Myung-ryul LEE
-
Publication number: 20220160703Abstract: The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in immunotherapy, particularly where the disease is accompanied by elevated levels of NQO1. In particular, embodiments where an immunotherapy, such as a heckpoint inhibitor, are combined with a NQO1 bioactivatable drug.Type: ApplicationFiled: March 18, 2020Publication date: May 26, 2022Applicants: The Board of Regents of The University of Texas System, Indiana University Research and Technology Corporation, The Board of Trustees of the University of IllinoisInventors: Yang-Xin FU, Xiumei HUANG, David BOOTHMAN, Paul J. HERGENROTHER, Xiaoguang LI, Lingxiang JIANG
-
Publication number: 20220112203Abstract: Disclosed are novel compounds that accumulate in Gram-negative bacteria. Also disclosed are method of antimicrobial treatment using the compounds.Type: ApplicationFiled: May 3, 2021Publication date: April 14, 2022Applicant: The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, Michelle Richter, Andrew Riley, Bryon S. Drown, Martin Chavez, Sarah Tasker, Alfredo Garcia